RespireRx Pharmaceuticals Inc. to Present at BIO CEO &
Investor Conference 2017
CEO to review dronabinol, a Phase 3-ready medicine for the
treatment of obstructive sleep apnea, and provide pipeline
update
GLEN ROCK, NJ-(Marketwired - Feb 10, 2017) - RespireRx
Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"),
a leader in the development of medicines for the treatment of
respiratory disorders for which there are no approved
pharmaceuticals, particularly sleep apneas and respiratory
depression resulting from pain management medicines and
disabilities such as spinal cord injury, announces that the
Company's President, Chief Executive Officer and Vice Chairman of
the Board of Directors, James S. Manuso, Ph.D., will present at the
BIO CEO & Investor Conference 2017 on Monday, February 13, 2017
at 1:00 PM Eastern Standard Time. The Conference is sponsored by
the Biotechnology Innovation Organization. Presentations will be
held at the Waldorf Astoria Hotel in New York from February 13-14,
2017.
Dr. Manuso will discuss results from the successfully completed
PACE Phase 2B trial, conducted by Dr. David Carley and colleagues
at the University of Illinois at Chicago and Northwestern
University, in which dronabinol (oral) was tested for the treatment
of obstructive sleep apnea ("OSA"). In addition, Dr. Manuso will
discuss results from a successfully completed Phase 2A trial in
which acutely administered CX-1739 (oral) reduced opioid induced
respiratory depression in a clinical model of chronic opioid
consumption. He will also provide background information and
descriptions of other product pipeline candidates.
Dr. Manuso's presentation will be available by live webcast
streaming online. To access the live audio webcast, log onto the
RespireRx website at www.respirerx.com, click on the investors tab
and follow the links this press release and click the link
http://www.veracast.com/webcasts/bio/ceoinvestor2017/36118482417.cfm
The webcast replay will be available one hour after conclusion
of the live event and the replay will expire on May 15, 2017.
A copy of the slide presentation to be presented at the
conference will be submitted to the Securities and Exchange
Commission in a Current Report on Form 8-K prior to the
presentation and will also be available in the investors section of
the RespireRx website.
About RespireRx Pharmaceuticals Inc.
RespireRx Pharmaceuticals Inc. is a leader in the development of
medicines for respiratory disorders, with a focus on sleep apneas
and drug-induced respiratory depression. The Company owns patents
and patent applications, and holds exclusive licenses, for certain
families of chemical compounds that claim the chemical structures
and their use in the treatment of these and other disorders.
Pending additional funding, during 2017, the Company plans to: 1)
meet with the FDA to discuss its Phase 3 clinical trial program to
test the safety and efficacy of dronabinol (oral) for the treatment
of OSA; 2) file an IND and initiate a Phase 2 clinical trial
investigating the ability of CX717 to improve breathing in patients
with spinal cord injury; and 3) file an IND and initiate a Phase 2
clinical trial investigating the ability of CX1739 to reduce
central sleep apnea in patients taking chronic opioids.
RespireRx's pharmaceutical candidates in development are derived
from two platforms, as described below.
The first platform is the class of compounds known as
cannabinoids, including dronabinol. Under a license agreement with
the University of Illinois, the Company has rights to patents
claiming the use of cannabinoids for the treatment of sleep-related
breathing disorders. As reported in a press release and on Form 8-K
on December 23, 2016, Dr. David Carley and colleagues at the
University of Illinois at Chicago and Northwestern University
successfully completed the PACE (Pharmacotherapy of Apnea by
Cannabimimetic Enhancement) trial, a potentially pivotal, six week,
double-blind, placebo-controlled Phase 2B study of dronabinol for
the treatment of OSA. Dronabinol significantly improved the primary
outcome measures of Apnea Hypopnea Index ("AHI"), daytime
sleepiness as measured by the Epworth Sleepiness Scale ("ESS") and
overall patient satisfaction as measured by the Treatment
Satisfaction Questionnaire for Medications ("TSQM"). This study was
fully funded by the National Heart, Lung and Blood Institute of the
National Institutes of Health. The Company did not manage or fund
this clinical trial.
In an earlier placebo-controlled, dose-ascending Phase 2A
clinical study conducted by the Company, dronabinol produced a
statistically significant reduction in the AHI, the primary
therapeutic end-point, and was observed to be safe and
well-tolerated in a group of patients with OSA.
The second platform of medicines being developed by RespireRx is
a class of proprietary compounds known as ampakines that act to
enhance the actions of the excitatory neurotransmitter glutamate at
AMPA glutamate receptor sites in the brain. Several ampakines in
both oral and injectable form are being developed by the Company
for the treatment of a variety of breathing disorders. In a
recently completed Phase 2A clinical trial, acute administration of
CX-1739 (oral) reduced the respiratory depression produced by
remifentanil, a potent opioid, in a clinical model of chronic
opioid consumption, without altering its analgesic effects.
Furthermore, ampakines have been demonstrated to improve breathing
in animal models of disorders such as spinal cord injury, Pomp
Disease, and perinatal respiratory distress. The Company's
compounds belong to a new class of ampakines that do not display
the undesirable side effects previously reported for earlier
generations of ampakines.
Additional information about the Company and the matters
discussed herein can be obtained on the Company's web-site at
www.RespireRx.com or in the Company's filings with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov.
Comments by the Company's President and Chief Executive
Officer
Dr. James S. Manuso, commented, "We look forward to advancing
the many initiatives RespireRx is undertaking throughout the course
of 2017. Now that the Company is Phase 3-ready with respect to the
final clinical and regulatory development of dronabinol for the
treatment of obstructive sleep apnea, commercialization and
potential partnering plans may be initiated. With dronabinol's
Phase 3 trial on the horizon, along with two Phase 2 or Phase
2-ready ampakine medicines in development, there are numerous
strategic and operational milestones on the calendar. In 2017 we
will continue to focus on the clinical and regulatory development
of the Company's two proprietary platforms for addressing unmet
needs in the sleep apnea and opioid-induced respiratory depression
markets. In addition, we will continue to support the scientific
research and pre-clinical development upon which our company is
based. I look forward to reporting to you our progress in the
months ahead."
Special Note Regarding Forward-Looking Statements: Certain
statements included or incorporated by reference in this news
release, including information as to the future financial or
operating performance of the Company and its drug development
programs, constitute forward-looking statements. The words
"believe," "expect," "anticipate," "contemplate," "target," "plan,"
"intend," "continue," "budget," "estimate," "may," "schedule" and
similar expressions identify forward-looking statements.
Forward-looking statements include, among other things, statements
regarding future plans, targets, estimates and assumptions.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by the
Company, are inherently subject to significant business, economic
and competitive uncertainties and contingencies. Many factors could
cause the Company's actual results to differ materially from those
expressed or implied in any forward-looking statements made by, or
on behalf of, the Company. Due to these various risks and
uncertainties, actual events may differ materially from current
expectations. Investors are cautioned that forward-looking
statements are not guarantees of future performance and,
accordingly, investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
Forward-looking statements are made as of the date of this news
release and the Company disclaims any intent or obligation to
update publicly such forward-looking statements, whether as a
result of new information, future events or results or
otherwise.
Company Contact: Jeff Margolis Vice-President, Treasurer and
Secretary Telephone: (917) 834-7206 E-mail:
jmargolis@respirerx.com
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2024 to May 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From May 2023 to May 2024